The Toronto General Hospital is a major teaching hospital in Toronto, Ontario, Canada and the flagship campus of University Health Network.

There are 417 beds in Toronto General Hospital.

During the past decade, Toronto General Hospital conducted 283 clinical trials. In the 10-year time frame, 283 clinical trials started and 107 clinical trials were completed, i.e. on average, 37.8% percent of trials that started reached the finish line to date. In the past 5 years, 109 clinical trials started and 58 clinical trials were completed. i.e. 53.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Toronto General Hospital" #1 sponsor was "University Health Network, Toronto" with 163 trials, followed by "Gilead Sciences" with 22 trials sponsored, "NCIC Clinical Trials Group" with 16 trials sponsored, "Boehringer Ingelheim" with 15 trials sponsored and "Abbott Medical Devices" with 15 trials sponsored. Other sponsors include 342 different institutions and companies that sponsored additional 202 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Toronto General Hospital" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 38 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 19 trials as a collaborator, "University Health Network, Toronto" with 13 trials as a collaborator, "Toronto General Hospital" with 10 trials as a collaborator and "University of Toronto" with 10 trials as a collaborator. Other collaborators include 389 different institutions and companies that were collaborators in the rest 286 trials.

According to Clinical.Site data, the most researched conditions in "Toronto General Hospital" are "HIV Infections" (26 trials), "Lung Cancer" (20 trials), "Heart Failure" (14 trials), "Pulmonary Arterial Hypertension" (13 trials) and "Coronary Artery Disease" (12 trials). Many other conditions were trialed in "Toronto General Hospital" in a lesser frequency.

Most popular intervention types in "Toronto General Hospital" are "Drug" (300 trials), "Device" (96 trials), "Other" (83 trials), "Procedure" (43 trials) and "Biological" (25 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (77 trials), "placebo" (9 trials), "Lamivudine" (5 trials), "FTC/TDF" (4 trials) and "JNJ-56136379" (4 trials). Other intervention names were less common.

The vast majority of trials in "Toronto General Hospital" are 548 trials for "All" genders, 18 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are 130 active trials in "Toronto General Hospital". 7 are not yet recruiting, 71 are recruiting, 47 are Active, not recruiting, and 5 are Enrolling by invitation. In total, there were 344 completed trials in Toronto General Hospital, 4 suspended trials, and 49 terminated clinical trials to date.

Out of the total trials that were conducted in Toronto General Hospital, 27 "Phase 1" clinical trials were conducted, 132 "Phase 2" clinical trials and 173 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 35 trials, and there were also 128 trials that are defined as “Not Applicable".